echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ZSP1273 Tablets, a subsidiary of Zhongsheng Pharmaceutical, received the US FDA Clinical Trial Approval Notice

    ZSP1273 Tablets, a subsidiary of Zhongsheng Pharmaceutical, received the US FDA Clinical Trial Approval Notice

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 1, Zhongsheng Pharmaceutical issued a corporate announcement.


    ZSP1273 is a kind of innovative drug with a clear mechanism of action and independent intellectual property rights developed by Zhongsheng Ruichuang for major sudden infectious diseases - influenza A and human avian influenza


    ZSP1273 has a strong broad-spectrum anti-influenza A virus activity in vitro, and its inhibitory ability to various influenza A viruses is significantly better than that of the same target compound and the neuraminidase inhibitor oseltamivir; the in vivo efficacy test is also comparable to the same.


    In terms of drug resistance, ZSP1273 also showed obvious advantages


    ZSP1273 tablets have completed Phase I and II clinical studies in China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.